Abstract

Conjugation of serum albumin or one of its ligands (such as fatty acid) has been an effective strategy to prolong the serum half-lives of drugs via neonatal Fc receptor (FcRn)–mediated recycling of albumin. So far, fatty acid (FA) has been effective in prolonging the serum half-lives for therapeutic peptides and small proteins, but not for large therapeutic proteins. Very recently, it was reported a large protein conjugated to FA competes with the binding of FcRn with serum albumin, leading to limited serum half-life extension, because primary FA binding sites in serum albumin partially overlap with FcRn binding sites. In order to prevent such competition, longer linkers between FA and the large proteins were required. Herein, we hypothesized that small proteins do not cause substantial competition for FcRn binding to albumin, resulting in the extended serum half-life. Using a small protein (28 kDa), we investigated whether the intramolecular distance in FA-protein conjugate affects the FcRn binding with albumin and serum half-life using linkers with varying lengths. Unlike with the FA-conjugated large protein, all FA-conjugated small proteins with different linkers exhibited comparable the FcRn binding to albumin and extended serum half-life.

Highlights

  • IntroductionTherapeutic proteins are rapidly eliminated from the blood of patients due to several mechanisms, including renal filtration, proteolysis, intracellular degradation, and immune responses, which result in short serum half-lives [2,3]

  • Therapeutic proteins have been widely used for the treatment of human diseases [1]

  • We chose Superfolder Green Fluorescent Protein (sfGFP) as a small model protein to investigate the competition to binding of FcRn to serum albumin and the serum half-life extension upon fatty acid conjugation

Read more

Summary

Introduction

Therapeutic proteins are rapidly eliminated from the blood of patients due to several mechanisms, including renal filtration, proteolysis, intracellular degradation, and immune responses, which result in short serum half-lives [2,3]. Such short serum half-lives of therapeutic proteins result in the need for frequent administration [2,3,4]. The extension of the serum half-life of therapeutic proteins is very important in developing new therapeutic proteins [2,4,5].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call